Fundraising FoxMESA VERDE VENTURE PARTNERS
Venture capitalLa Jolla · Seed–Series A · 8 people tracked
Find your way into MESA VERDE VENTURE PARTNERS
Each arrow is one introduction. Sign up to fill in the first one.
Ask Dede Willis to introduce you to Randy Berholtz
You →Dede · together at Orbit Genomics →Randy
Sign up to find every way you can get introduced to MESA VERDE VENTURE PARTNERS
- Your email: who you already know at MESA VERDE VENTURE PARTNERS, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the MESA VERDE VENTURE PARTNERS team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Mesa Verde Venture Partners invests in a diversified portfolio of early-stage life sciences companies, partnering with entrepreneurs to build successful businesses. The firm draws on over 20 years of experience and more than 20 life sciences investments. It concentrates on biomedical companies in Southern California, the Southwest, and other geographies traditionally underrepresented in life sciences venture capital. Areas of interest span pharmaceuticals, medical devices, diagnostics, life science enabling tools, and digital health, aiming to back products that improve human health while generating strong returns for investors.
Source: firm website, verified Sep 27, 2026.
Team · 8 people
from the firm's website & curated & public directories
What they invest in
from 15 of 18 portfolio companiesBiotech ×14Healthtech ×10Medical Devices ×4Digital Health ×3Consumer ×1Deep Tech ×1Direct to Consumer ×1Wellness & Fitness ×1
HQs:United States×13
Investments · 18 tracked
founders shown can be your intro pathBy year:2024 · 12019 · 12018 · 12017 · 12016 · 12015 · 16 dated
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.
BiotechHealthtechLa Jolla, US
Kenneth A. Stauderman(Co-founder)inGonul Velicelebi(Co-founder)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Michael J. Dunn(Executive Officer)inStephen Bardin(Chief Financial Officer)in
Co-investorsAisling CapitalRevelation PartnersSanderling VenturesClarus LifesciencesClarus VenturesOrbiMed
Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression.
BiotechDigital HealthHealthtechMedical DevicesVista, US
Thierry Dervieux(Executive Officer)inWendy Swedick(Executive Officer)Fortunato R. Rocca(Executive Officer, Director)John Aballi(President & CEO)inJeffrey Black(Chief Financial Officer and Corporate Secretary)in
BoardJames L.L. Tullis(Director)in
Co-investorsCottonwood Technology FundEPIC VENTURESH.I.G. CapitalH.I.G. HealthBridge PartnersSun Mountain CapitalTullis Health Investors
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesLongitude CapitalNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture Partners+4 more
Alastin is a scientific skincare brand offering clinically formulated products, including treatments for skin discoloration, hydrating and soothing formulations, and tinted sun protection, built around its proprietary TriHex Technology.
BiotechConsumerDirect to ConsumerWellness & FitnessDel Mar, US
Diane GoostreeinScott L. Glenn(Executive Officer, Director)
BoardTed Schwarz(Director)Maryanne K. Sorge(Director)Mark G. Rubin(Director)Cam Garner(Director)
Exact Sciences develops and runs laboratory tests and clinical studies for cancer detection and treatment, serving patients and health care professionals in oncology.
BiotechDigital HealthMedical DevicesSan Diego, US
Tony Broad(Executive Officer)Francois Ferre(Director)Nick Ecos(Executive Officer, Director)Joseph Markee(Executive Officer, Director)
Co-investorsBioBrit
Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy for relapsed/refractory AL amyloidosis and other plasma cell-driven immune diseases.
BiotechHealthtechLos Angeles, US
Gabriel Morris(Chief Financial Officer)inIlya Rachman(Founder & Chief Executive Officer)inDavid Marks(Chief Medical Officer)
BoardCarey Ng(Director)Magda Marquet(Director)Jane Buchan(Director)
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)inSean Ainsworth(Chief Executive Officer)inRobert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in
Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+6 more
Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.
Co-investorsAisling CapitalARCH Venture PartnersProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURESFoley Ventures+2 more
Lineagen provides genetic testing and optical genome mapping services for clinical diagnosis and research applications.
BiotechDigital HealthHealthtechMedical DevicesSalt Lake City, US
Gayland Moffat(Executive Officer)Michael S. Paul(Executive Officer, Director)
BoardMichael Fitzgerald(Director)Fred A. Middleton(Director)Mary C. Tanner(Director)Michael Walsh(Director)
Co-investorsMountain Group CapitalHealthQuest Capital
Merck is a science-led pharmaceutical company that develops medicines and vaccines for patients globally.
BiotechHealthtechMedical Devices
Rob Davisin
Co-investorsSanderling Ventures
BiotechDublin 1
Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)
Co-investorsAisling CapitalEcoR1 CapitalFrazier Life SciencesLongitude CapitalNovartis Venture Fund
Clinical-stage oncology company developing cancer treatments
BiotechDel Mar, US
Dana McGowan(Treasurer and Secretary)Karen Lundgren(Vice President and Chief Scientific Officer)Lauren G. Otsuki(Chief Business Officer)inJames Freddo(Chief Medical Officer)James B. Breitmeyer, M.D., Ph.D.(President and Chief Executive Officer)
BoardDavid F. Hale(Director)
Co-investorsVedanta Capital
SMPA (Sunovion) is a pharmaceutical company focused on drug discovery, development, and commercialization aimed at bringing novel medicines to patients with unmet health needs.
BiotechHealthtech
Supernus is a pharmaceutical company that develops and markets products in the biosciences and pharmaceutical industry.
BiotechHealthtechRockville, US
Jack A. Khattar(Executive Officer, Director)Padmanabh P. Bhatt, Ph.D.(Executive Officer)inPaolo Baroldi, M.D., Ph.D.(Executive Officer)Tami T. Martin, R.N., Esq.(Executive Officer)Russell P. Wilson(Executive Officer)in
BoardMichael B. Sheffery, Ph.D.(Director)
Co-investorsNew Enterprise Associates (NEA)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Equillium BioMedipacsParadigm Diagnostics
Exits · 4
3 IPOs · 1 acquisitions · showing 3CalcimedicaNASDAQ: CALCExagenNASDAQ: XGNMirum PharmaceuticalsNASDAQ: MIRM
Portfolio news
latest coverage across their companiesExagen · biospace.com · May 11, 2026
Immusoft · immusoft.com · Mar 30, 2026
Merck · merck.com · Mar 19, 2026
Frequently asked questions
- How many investments has MESA VERDE VENTURE PARTNERS made?
- MESA VERDE VENTURE PARTNERS has 18 tracked investments, 4 of which have exited.
- What stage does MESA VERDE VENTURE PARTNERS invest at?
- MESA VERDE VENTURE PARTNERS invests at the Seed, Series A stages.
- What sectors does MESA VERDE VENTURE PARTNERS focus on?
- MESA VERDE VENTURE PARTNERS focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is MESA VERDE VENTURE PARTNERS located?
- MESA VERDE VENTURE PARTNERS is headquartered in La Jolla, US.
- Who does MESA VERDE VENTURE PARTNERS co-invest with?
- MESA VERDE VENTURE PARTNERS most often shares deals with Aisling Capital, Frazier Life Sciences, Longitude Capital, among 25 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Black Opal Ventures is a venture capital firm founded in 2021 by Tara Bishop and Eileen Tanghal, investing at the intersection of technology and healthcare.